Gonadorelin

Overview

Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), also historically called luteinizing hormone-releasing hormone (LHRH). GnRH is the natural decapeptide (ten amino acids) released by the hypothalamus that sits at the very top of the reproductive hormone cascade. Gonadorelin is chemically identical to endogenous human GnRH, so it is not an analog or a modified peptide. It is a manufactured copy of a hormone the body already makes.

When it reaches the anterior pituitary, GnRH triggers release of the two gonadotropins: luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These in turn act on the ovaries and testes to drive sex-hormone production (estrogen, progesterone, testosterone) and gamete development. Because gonadorelin is the natural signal at the top of this axis, it has been used both diagnostically (to test whether the pituitary can respond) and therapeutically (to drive ovulation in certain forms of infertility).

A closely related molecule, Kisspeptin, acts one step upstream of gonadorelin: kisspeptin stimulates the hypothalamic neurons that release GnRH. Gonadorelin should also not be confused with the long-acting GnRH agonists (such as leuprolide/leuprorelin, goserelin, triptorelin) or GnRH antagonists (such as cetrorelix, ganirelix, degarelix), which are designed to suppress the axis rather than stimulate it.

Chemistry and structure

Gonadorelin is a linear decapeptide with the sequence:

pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2

The N-terminus is a cyclised pyroglutamate (pGlu, written as 5-oxo-proline) and the C-terminus is an amide (Gly-NH2). This is the exact sequence of native human GnRH/LHRH.

Because the native sequence is rapidly broken down by peptidases, gonadorelin has a very short biological action measured in minutes. This is the key practical difference from the synthetic GnRH agonists, which were deliberately re-engineered (e.g., D-amino-acid substitutions) to resist degradation and act for hours to months.

Mechanism of action

Gonadorelin binds the GnRH receptor on pituitary gonadotroph cells. The downstream effect depends entirely on the pattern of exposure, which is one of the most important and counter-intuitive facts about this molecule.

• Pulsatile exposure stimulates. Native GnRH is normally secreted in brief bursts roughly every 60–120 minutes. Delivering gonadorelin in a similar pulsatile rhythm allows the receptor to recover between pulses, keeps GnRH-receptor expression up, and produces robust release of LH and FSH. This is the basis of the pulsatile fertility pump (Lutrepulse) and of GnRH stimulation testing.

• Continuous exposure suppresses (desensitisation). Sustained, non-pulsatile exposure to GnRH down-regulates and desensitises the receptor, so LH and FSH release falls and sex-hormone production is suppressed. This is the same principle exploited by long-acting GnRH agonists used (after an initial flare) to suppress the axis in conditions such as prostate cancer, endometriosis, and central precocious puberty.

In short, the same molecule can switch the reproductive axis on or off depending purely on timing. Gonadorelin's diagnostic and fertility uses rely on the pulsatile/short-burst mode; the suppression strategies are the domain of the engineered long-acting agonists and the antagonists.

Clinical and regulatory status and history

Gonadorelin's regulatory story is a mix of genuine historical approval and subsequent discontinuation, and it differs sharply between human and veterinary use, and between jurisdictions.

United States (FDA)

• Factrel (gonadorelin hydrochloride) was historically approved as a diagnostic agent for evaluating the functional capacity and response of the pituitary gonadotrophs (a "GnRH stimulation test"). The human Factrel product is no longer marketed. (The Factrel brand name now appears on a Zoetis veterinary product for cattle, which is a separate animal-drug approval under a New Animal Drug Application.)
• Lutrepulse / Lutropulse (gonadorelin acetate) was approved (originally via Ortho, later associated with Ferring) for inducing ovulation in women with primary hypothalamic amenorrhoea, administered as intravenous pulses via an infusion pump (the Zyklomat system). This product was later withdrawn from the market for commercial reasons, not because of a safety or efficacy problem, and is no longer available in the United States.

The practical result is that no actively marketed FDA-approved human gonadorelin product exists today. Because the human products were withdrawn for commercial rather than safety/efficacy reasons, gonadorelin appears in compounding-pharmacy contexts in the US, but the regulatory standing of that compounding is an unsettled interpretive question rather than a fresh approval.

European Union (EMA) and other countries

• Gonadorelin was never granted a centralised EU marketing authorisation through the EMA. It predates that system and existed as older national approvals in various European countries under brands such as Relefact, HRF, Cryptocur/Kryptocur, and Lutrepulse. Many of these national products have since been discontinued, and availability varies considerably by country. A gonadorelin European Pharmacopoeia monograph exists, reflecting recognised pharmaceutical identity rather than a current marketing authorisation.
• In Canada, a Lutrepulse (gonadorelin acetate) product for primary hypothalamic amenorrhoea has been documented, with a later subcutaneous-pump reintroduction reported, illustrating that availability is jurisdiction-specific and changes over time.

Veterinary medicine

Gonadorelin remains firmly established and approved in veterinary reproduction. Products such as Fertagyl, Cystorelin, and the veterinary Factrel are used in cattle for treating ovarian follicular cysts and for estrus/ovulation synchronisation in fixed-time artificial insemination programs (e.g., Ovsynch protocols). This veterinary use is robust and ongoing, in contrast to the discontinued human products.

Clinical evidence (human)

The strongest human evidence is in pulsatile GnRH for hypothalamic amenorrhoea:

A recurring theme is that pulsatile GnRH offers a relatively physiological route to ovulation with a low multiple-pregnancy rate compared with injectable gonadotropins — but it requires a pump and is logistically demanding, which contributed to its limited commercial uptake.

Safety and risks

Because gonadorelin is the body's own hormone given in physiological amounts, it has historically been considered relatively well tolerated in its approved diagnostic and pulsatile-fertility uses. Reported considerations include:

• Injection / infusion-site effects, headache, nausea, abdominal or flushing sensations, and lightheadedness.
• Hypersensitivity reactions, uncommon, but allergic responses have been described, particularly with repeated administration.
• Ovarian hyperstimulation and multiple pregnancy in the fertility (ovulation-induction) context. The risk is generally lower than with injectable gonadotropins because pulsatile GnRH preserves more of the body's natural feedback, but it is not zero, and one case of hyperstimulation in the Santoro series occurred with concurrent clomiphene.
• Pump-related and logistical risks for the pulsatile fertility route (indwelling catheter, infection, mechanical issues), which is part of why that modality was used sparingly.

A separate and important safety point concerns unapproved sources. Material sold online as "research" gonadorelin is not the discontinued FDA-approved medicine and carries no guarantee of identity, purity, sterility, or potency. None of the approved-use safety framing (clinical supervision, defined indications, monitoring) applies to unregulated supply. This page does not provide dosing, protocols, or sourcing guidance.

How it compares

Gonadorelin is best understood by its position in the reproductive axis relative to the molecules around it:

• Kisspeptin acts upstream of gonadorelin. Kisspeptin stimulates hypothalamic neurons to release endogenous GnRH, whereas gonadorelin is GnRH acting directly on the pituitary. Kisspeptin is largely investigational; gonadorelin has a real (if discontinued) approval history.
• GnRH agonists (leuprolide/leuprorelin, goserelin, triptorelin, nafarelin) are engineered, long-acting versions designed to cause sustained, non-pulsatile receptor exposure, used to suppress the axis after an initial flare. Gonadorelin, by contrast, is the native short-acting molecule used to stimulate it.
• GnRH antagonists (cetrorelix, ganirelix, degarelix) block the receptor for immediate suppression without a flare.

So three superficially similar "GnRH drugs" do opposite things: gonadorelin (pulsatile) turns the axis on, while agonists (continuous) and antagonists turn it off. For the broader context of how these agents fit into reproductive and hormonal health, see the Sexual & reproductive health hub.

Common misconceptions

---

This article is provided for educational purposes only and is not medical advice. Gonadorelin's approved human indications were managed under clinical supervision with defined protocols and monitoring. Nothing here should be interpreted as guidance to obtain or use gonadorelin outside of an approved, supervised context, and no dosing or sourcing information is provided. Regulatory status varies by jurisdiction and changes over time; verify current status with primary regulatory sources.